Autor: |
Brandon S. Walker, Robert L. Schmidt, Edward R. Ashwood, Brian R. Jackson, Danielle Lagrave |
Rok vydání: |
2015 |
Předmět: |
|
Zdroj: |
Prenatal Diagnosis. 35:440-446 |
ISSN: |
0197-3851 |
Popis: |
Objective The aim of this article is to determine the cost effectiveness of cell free DNA (cfDNA) as a replacement forintegrated screening using a societal cost perspective. Method This study used Monte-Carlo simulation with one-way and probabilistic sensitivity analysis. Results Cell free DNA is more effective and less costly than integrated screening. The incremental cost-effectivenessratio for cfDNA relative to the integrated test was $277955 per case detected (95th percent confidence interval $881882 to $532785). Conclusion Cell free DNA screening is a cost-effective replacement for maternal serum screening when the lifetimecosts of Down syndrome live births are considered. The adoption of cfDNA screening would save approximately$277955 for each additional case detected over integrated screening. © 2014 John Wiley & Sons, Ltd. Funding sources: NoneConflicts of interest: All of the authors are employees of ARUP laboratories, which provide a wide range of clinical laboratory tests including prenatal screening tests(both maternal serum screening and cfDNA). |
Databáze: |
OpenAIRE |
Externí odkaz: |
|